WAYPATH PHARMA LLC

Biotech · Private

Small-molecule drugs (MT1, MT3) that cross the blood-brain barrier and trigger glioblastoma cell death via metabolic disruption

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2565LactaLogics, Inc.—$1.1M
2566MUCOMMUNE, LLC——
2567Ichor Microbial Solutions, Inc.—$1.1M
2568WAYPATH PHARMA LLC——
2569SENEX BIOTECHNOLOGY, INC.—$1.0M
2570Decoy Therapeutics, Inc.—$1.0M
2571NEW HORIZON BIOTECH INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.